Ziltivekimab - Novo Nordisk
Alternative Names: COR 001; EX-6018; MEDI-5117; NN-6018; WBP-216Latest Information Update: 19 Aug 2024
At a glance
- Originator MedImmune
- Developer MedImmune; Novo Nordisk
- Class Anti-inflammatories; Anti-ischaemics; Antirheumatics; Cardiovascular therapies; Heart failure therapies; Monoclonal antibodies
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cardiovascular disorders; Heart failure
- Discontinued Autoimmune disorders; Rheumatoid arthritis
Most Recent Events
- 01 Apr 2024 Novo Nordisk initiates the phase III ATHENA trial for Heart failure in Argentina, Australia, France, Malaysia, Spain (SC) (NCT06200207)
- 01 Apr 2024 Phase-III clinical trials in Heart failure in Czech Republic, India, United Kingdom (SC) (NCT06200207)
- 01 Apr 2024 Novo Nordisk initiates the phase III ATHENA trial for Heart failure in the US, Bulgaria, Canada, Germany, Greece, and Poland (SC) (NCT06200207)